Abstract:Obesity is a worsening global health crisis leading to increased risk of long-term complications such as type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), dyslipidemia and cardiovascular disease. Identifying novel molecular mechanisms regulating the connection between obesity, hepatic insulin resistance and progression of NASH is critical to develop new therapeutic options for these patients. Previous work has shown that reversible N6-methyladenosine (m6A) RNA methylation patterns are altered in and regulate metabolic disease in the pancreatic beta cell and liver. However, these studies have primarily focused on the m6A writer proteins that direct placement of m6A methyl groups, while our study explores the role of m6A eraser protein AlkBH5 in regulating metabolic pathways in the liver. To test the hypothesis that hepatic ALKBH5 is required to maintain normal glucose homeostasis, insulin sensitivity and lipid metabolism under physiologic conditions and in response to metabolic stress we used liver-specific Alkbh5 knockout (A5KO) mice and evaluated changes in weight gain, body composition, glucose tolerance, insulin sensitivity, fasting insulin levels, and gluconeogenesis in response to a chow versus Western diet (WD). In physiologic conditions (chow), A5KO mice have decreased glucose tolerance with no other significant phenotypic changes compared to controls. Exposure to metabolic stress (WD) caused (1) greater weight gain with increased visceral fat in control compared to A5KO mice, (2) decreased glucose tolerance compared to chow in both genotypes, (3) decreased glucose mobilization in A5KO mice on WD compared to chow, with no significant differences in controls, and (4) no significant differences in global insulin sensitivity. These studies demonstrate that A5KO mice are protected against weight gain upon exposure to metabolic stress with decreased glucose tolerance and mobilization compared to controls, establishing a role for hepatic ALKBH5 in regulating glucose and lipid metabolism. Disclosure K.Aamodt: None. M.Polay: None. V.R.Salerno gonzales: None. R.Kulkarni: Advisory Panel; Novo Nordisk, Inversago, Biomea Fusion, Inc., REDD Pharma, Research Support; Inversago. Funding National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK007699-39, 5T32DK007260-45); Pediatric Endocrine Society

The deficiency of ALKBH5 contributes to hepatic lipid deposition by impairing VPS11-dependent autophagic flux

Loss of M6a Demethylase ALKBH5 Alleviates Hypoxia-Induced Pulmonary Arterial Hypertension Via Inhibiting Cyp1a1 Mrna Decay

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

DNA 6ma Demethylase ALKBH1 Orchestrates Fatty Acid Metabolism and Suppresses Diet-Induced Hepatic Steatosis.

Loss of M6a Demethylase ALKBH5 Promotes Post‐ischemic Angiogenesis Via Post‐transcriptional Stabilization of WNT5A

ALKBH5 attenuates mitochondrial fission and ameliorates liver fibrosis by reducing Drp1 methylation

Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis

ALKBH5 ameliorated liver fibrosis and suppressed HSCs activation via triggering PTCH1 activation in an m6A dependent manner

Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease

ALKBH5 suppresses autophagic flux via N6-methyladenosine demethylation of ZKSCAN3 mRNA in acute pancreatitis

Betaine alleviates nonalcoholic fatty liver disease (NAFLD) via a manner involving BHMT/FTO/m 6 A/ PGC1α signaling

Lipid Deposition in Liver Cells: the Influence of Short Form Augmenter of Liver Regeneration.

Lysine β-hydroxybutyrylation promotes lipid accumulation in alcoholic liver disease

ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1

Hepatic Lysosomal Acid Lipase Drives the Autophagy-Lysosomal Response and Alleviates Cholesterol Metabolic Disorder in ApoE Deficient Mice

Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma

1567-P: Hepatic ALKBH5 Regulation of Glucose and Lipid Metabolism

Α-Lipoic Acid Alleviates Hepatic Lipid Deposition by Inhibiting FASN Expression Via Mir-3548 in Rats

N6-methyladenosine RNA Modification in Nonalcoholic Fatty Liver Disease.

Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis

The Peptide AWRK6 Alleviates Lipid Accumulation in Hepatocytes by Inhibiting miR-5100 Targeting G6PC